Clinical trial
Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid…
NCT00388427 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00388427 |
|---|---|
| Title | Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies |
| Official title | Phase I Study of Cetuximab Plus Dasatinib (BMS-354825) in Advanced Solid Malignancies |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignant Solid Tumour |
| Intervention type | Drug |
| Interventions | Dasatinib (BMS-354825), Cetuximab (Erbitux, C225) |
| Enrollment | 31 |
| Start date | Jun 1, 2007 |
| Primary completion | Jul 1, 2009 |
| Completion | Feb 1, 2013 |
| First posted | Oct 16, 2006 |
| Last update posted | May 28, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: